{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:48:16Z","timestamp":1788634096689,"version":"build-2803163510"},"reference-count":23,"publisher":"Bioscientifica","issue":"11","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:p>Malignant pleural effusion (MPE) from differentiated thyroid cancer (DTC) is rare and carries a poor prognosis. This study evaluated clinical outcomes and the impact of multikinase inhibitor (MKI) therapy in patients with MPE from DTC. In this retrospective cohort study of 184 DTC patients with lung metastases, 31 (17%) had MPE. After excluding 10 with non-malignant effusion, 174 were analyzed. Patients with MPE were older (P &amp;lt; 0.001) at DTC diagnosis, had higher T stage (P = 0.004), developed pleural metastases earlier (P = 0.016), and had more frequent macro- and polymetastatic lung lesions (P &amp;lt; 0.001) than those without MPE. All MPE cases were radioactive iodine-refractory and developed a median of 6.3 years after DTC diagnosis. Symptomatic MPE occurred in 22 patients (71%), all requiring drainage, while 9 (29%) had asymptomatic MPE. Symptomatic MPE was associated with worse overall survival (OS) compared to patients without MPE (adjusted hazard ratio (HR) 4.62, 95% confidence interval (CI) 2.49\u20138.57, P &amp;lt; 0.001). Notably, patients initiating MKI therapy for symptomatic MPE had the worst OS (adjusted HR 9.78, 95% CI: 3.52\u201327.13, P &amp;lt; 0.001). Median OS after MPE diagnosis was 13 months. Symptomatic MPE also had worse post-MPE survival compared to asymptomatic MPE (adjusted HR 5.73, 95% CI: 1.52\u201321.52, P = 0.009). MKI therapy did not significantly improve OS or progression-free survival after MPE onset. MPE in DTC patients with lung metastases indicates poor prognosis, especially when symptomatic. MKI therapy showed limited survival benefits after MPE onset. Early identification and proactive management of patients at high risk of MPE may improve outcomes.<\/jats:p>","DOI":"10.1530\/erc-25-0190","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T10:51:03Z","timestamp":1761303063000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3921-8635","authenticated-orcid":true,"given":"Chae A","family":"Kim","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5074-3561","authenticated-orcid":true,"given":"Jungmin","family":"Yoo","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8404-7759","authenticated-orcid":true,"given":"Won Gu","family":"Kim","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4982-4441","authenticated-orcid":true,"given":"Tae Yong","family":"Kim","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4544-1750","authenticated-orcid":true,"given":"Won Bae","family":"Kim","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-107X","authenticated-orcid":true,"given":"Min Ji","family":"Jeon","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"2026070909434642200_bib1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1716883","article-title":"Outpatient talc administration by indwelling pleural catheter for malignant effusion","volume":"378","author":"Bhatnagar","year":"2018","journal-title":"N Engl J Med"},{"key":"2026070909434642200_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24260","article-title":"Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT","volume":"24","author":"Bhatnagar","year":"2020","journal-title":"Health Technol Assess"},{"key":"2026070909434642200_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2026070909434642200_bib4","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026070909434642200_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/LBR.0000000000000999","article-title":"American association of bronchology and interventional pulmonology essential knowledge in interventional pulmonology series: selected topics in malignant pleural disease","volume":"32","author":"Chrissian","year":"2025","journal-title":"J Bronchology Interv Pulmonol"},{"key":"2026070909434642200_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026070909434642200_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"2026070909434642200_bib8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3803\/EnM.2011.26.4.330","article-title":"Four cases of malignant pleural effusion in patients with papillary thyroid carcinoma","volume":"26","author":"Jeon","year":"2011","journal-title":"Endocrinol Metab"},{"key":"2026070909434642200_bib9","doi-asserted-by":"crossref","first-page":"S1146","DOI":"10.21037\/jtd.2017.06.52","article-title":"Asymptomatic malignant pleural effusion: to observe or to manage","volume":"9","author":"Keshishyan","year":"2017","journal-title":"J Thorac Dis"},{"key":"2026070909434642200_bib10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1089\/thy.2016.0676","article-title":"Growth kinetics of macronodular lung metastases and survival in differentiated thyroid carcinoma","volume":"27","author":"Kim","year":"2017","journal-title":"Thyroid"},{"key":"2026070909434642200_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3803\/EnM.2018.33.2.287","article-title":"Prognosis of differentiated thyroid carcinoma with initial distant metastasis: a multicenter study in Korea","volume":"33","author":"Kim","year":"2018","journal-title":"Endocrinol Metab"},{"key":"2026070909434642200_bib12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S2213-8587(25)00064-6","article-title":"Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement","volume":"13","author":"Leboulleux","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070909434642200_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000441647","article-title":"Cytologic features and immunocytochemical profiles of malignant effusions with metastatic papillary thyroid carcinoma: a case series from a single institution","volume":"59","author":"Lew","year":"2015","journal-title":"Acta Cytol"},{"key":"2026070909434642200_bib14","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1089\/thy.2013.0703","article-title":"Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma","volume":"24","author":"Liu","year":"2014","journal-title":"Thyroid"},{"key":"2026070909434642200_bib15","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0147","article-title":"Pleural metastases from differentiated thyroid cancer: clinical features and long-term outcomes","volume":"14","author":"Liu","year":"2025","journal-title":"Eur Thyroid J"},{"key":"2026070909434642200_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncy.22654","article-title":"Malignant effusions secondary to metastatic thyroid carcinomas: a review of 15 cases","volume":"131","author":"Mustafa","year":"2023","journal-title":"Cancer Cytopathol"},{"key":"2026070909434642200_bib17","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/thorax-2022-219784","article-title":"British thoracic society guideline for pleural disease","volume":"78","author":"Roberts","year":"2023","journal-title":"Thorax"},{"key":"2026070909434642200_bib18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1089\/thy.2015.0395","article-title":"Time course and predictors of structural disease progression in pulmonary metastases arising from follicular cell-derived thyroid cancer","volume":"26","author":"Sabra","year":"2016","journal-title":"Thyroid"},{"key":"2026070909434642200_bib19","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.21037\/gs-24-269","article-title":"Lenvatinib treatment strategy for thyroid carcinoma with malignant pleurisy: a case report","volume":"13","author":"Sakamoto","year":"2024","journal-title":"Gland Surg"},{"key":"2026070909434642200_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070909434642200_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0042-1746175","article-title":"Treatment response following radioactive iodine therapy in miliary versus macronodular pulmonary metastases in papillary thyroid carcinoma","volume":"21","author":"Sunny","year":"2022","journal-title":"World J Nucl Med"},{"key":"2026070909434642200_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1507\/endocrj.EJ15-0631","article-title":"Outcome and characteristics of patients with malignant pleural effusion from differentiated thyroid carcinoma","volume":"63","author":"Tomoda","year":"2016","journal-title":"Endocr J"},{"key":"2026070909434642200_bib23","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/00007611-199411000-00010","article-title":"Pleural effusion in patients with differentiated papillary thyroid cancer","volume":"87","author":"Vassilopoulou-Sellin","year":"1994","journal-title":"South Med J"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/11\/ERC-25-0190.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/11\/ERC-25-0190.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0190\/505647\/erc-25-0190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0190\/505647\/erc-25-0190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:43:58Z","timestamp":1783604638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/11\/e250190\/75472\/Clinical-outcomes-of-malignant-pleural-effusion-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0190","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"article-number":"e250190"}}